DIVI'S LABORATORIES LTD.
NSE : DIVISLABBSE : 532488ISIN
CODE : INE361B01024Industry : Pharmaceuticals & DrugsHouse
: Divis Labs
BSE3791.952.45 (+0.06 % )
PREV CLOSE (Rs.) 3789.50
OPEN PRICE (Rs.) 3799.95
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 4791
TODAY'S LOW / HIGH (Rs.)
52 WK LOW / HIGH (Rs.)
NSE3793.50 3.55 (+0.09 % )
PREV CLOSE(Rs.) 3789.95
OPEN PRICE (Rs.) 3794.75
BID PRICE (QTY) 3793.50 (27 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 276308
TODAY'S LOW / HIGH(Rs.)
52 WK LOW / HIGH (Rs.)
Company News
| Date | Heading | Details |
|---|---|---|
| 26-Apr-2024 | Divi's Laboratories surges on planning for capacity addition at manufacturing facility | <p style="text-align: justify;">Divi's Laboratories is currently trading at Rs. 3988.50, up by 147.75 points or 3.85% from its previous closing of Rs. 3840.75 on the BSE.</p><p style="text-align: justify;">The scrip opened at Rs. 3855.00 and has touched a high and low of Rs. 4018.00 and Rs. 3840.75 respectively. So far 17087 shares were traded on the counter.</p><p style="text-align: justify;">The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 4072.35 on 04-Jan-2024 and a 52 week low of Rs. 3050.15 on 22-May-2023.</p><p style="text-align: justify;">Last one week high and low of the scrip stood at Rs. 4018.00 and Rs. 3674.20 respectively. The current market cap of the company is Rs. 104872.04 crore.</p><p style="text-align: justify;">The promoters holding in the company stood at 51.92%, while Institutions and Non-Institutions held 36.89% and 11.19% respectively.</p><p style="text-align: justify;">Divi's Laboratories is in the process of entering into a long-term supply agreement with a customer and is planning for capacity addition at its manufacturing facility with an estimated investment between Rs 650 crore to Rs 700 crore, to be funded from internal accruals. The proposed facility is expected to be operational around January 2027. Due to the confidentiality agreement signed with the customer, the Company is not permitted to disclose any further quantitative details.</p><p style="text-align: justify;">Divi's Laboratories is one of the leading pharmaceutical companies in the world.</p> |
| 25-Apr-2024 | Divi's Laboratories planning for capacity addition at manufacturing facility | <p style="text-align: justify;">Divi's Laboratories is in the process of entering into a long-term supply agreement with a customer and is planning for capacity addition at its manufacturing facility with an estimated investment between Rs 650 crore to Rs 700 crore, to be funded from internal accruals. The proposed facility is expected to be operational around January 2027. Due to the confidentiality agreement signed with the customer, the Company is not permitted to disclose any further quantitative details.</p><p style="text-align: justify;">Divi's Laboratories is one of the leading pharmaceutical companies in the world.</p> |
| 25-Apr-2024 | Divi's Laboratories informs about disclosure | <p style="text-align: justify;">Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, Divi's Laboratories has submitted the details as required under Para B of Part A of Schedule III of the Regulations read with Circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 11-Apr-2024 | Divi's Laboratories informs about certificate | <p style="text-align: justify;">Divi's Laboratories has informed that it enclosed certificate dated April 10, 2024 obtained from V. Bhaskara Rao & Co., Practicing Company Secretaries for the year ended March 31, 2024, pursuant to Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p><div style="text-align: justify;"><br></div> |
| 30-Mar-2024 | Divi's Laboratories informs about closure of trading window | <p style="text-align: justify;">Pursuant to the Company's Code of Conduct for Prevention of Insider Trading (the Code), Divi's Laboratories has informed that the Trading Window for dealing in securities of the Company will remain Closed for all Designated Persons and their Immediate Relatives, as well as Insiders covered under the Code, from April 01, 2024, till 48 hours after the declaration of audited financial results for the fourth quarter and year ending March 31, 2024. The date of Board meeting for declaration of the financial results of the Company for the fourth quarter and year ending March 31, 2024, will be intimated in due course.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 04-Mar-2024 | Divi's Laboratories informs about notice of postal ballot | <div style="text-align: justify;">Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to the outcome of meeting of the Board of Directors dated February 10, 2024, Divi's Laboratories has submitted the Postal Ballot Notice dated February 10, 2024 (Notice) to seek approval of Members of the Company for the following resolutions: Reappointment of Prof. Sunaina Singh (DIN: 08397250) as an Independent Director of the Company Special Resolution; Appointment of Dr. S. Devendra Rao (DIN: 10481393) as Whole-time Director, designated as ‘Whole-time Director (Manufacturing)' of the Company and approval of the remuneration payable to him; and approval to hold and continue to hold office or place of profit by S. Swaroop Krishna in the Company. The e-voting period commences on Wednesday, March 06, 2024, at 9:00 am (IST) and ends on Thursday, April 04, 2024, at 5.00 pm (IST). The e-voting shall be disabled by Kfintech for e-voting thereafter. Results of the Postal Ballot will be announced on or before 5.00 pm (IST) on or before Saturday, April 06, 2024. The Postal Ballot Notice along with e-voting instructions is available on the Company's website at https://www.divislabs.com and on the website of Kfintech https://evoting.kfintech.com.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div> |
| 12-Feb-2024 | Divi's Laboratories reports 17% rise in Q3 consolidated net profit | <p style="text-align: justify;">Divi's Laboratories has reported results for third quarter ended December 31, 2023 (Q3FY24).</p><p style="text-align: justify;">The company has reported 15.48% rise in its net profit at Rs 358 crore for the third quarter ended December 31, 2023 as compared to Rs 310 crore for the same quarter in the previous year. Total income of the company increased by 5.26% at Rs 1902 crore for Q3FY24 as compared Rs 1807 crore for corresponding quarter of the previous year. </p><p style="text-align: justify;">On consolidated basis, the company has reported 16.99% rise in net profit at Rs 358 crore for Q3FY24 as compared to Rs 306 crore for the same quarter in the previous year. Total income of the company increased by 7.08% at Rs 1950 crore for Q3FY24 as compared Rs 1821 crore for corresponding quarter of the previous year.</p> |
| 12-Feb-2024 | Divi's Laboratories surges on reporting 17% rise in Q3 consolidated net profit | <p style="text-align: justify;">Divi's Laboratories is currently trading at Rs. 3751.95, up by 100.95 points or 2.76% from its previous closing of Rs. 3651.00 on the BSE.</p><p style="text-align: justify;">The scrip opened at Rs. 3650.00 and has touched a high and low of Rs. 3822.70 and Rs. 3648.70 respectively. So far 25265 shares were traded on the counter.</p><p style="text-align: justify;">The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 4072.35 on 04-Jan-2024 and a 52 week low of Rs. 2730.00 on 14-Mar-2023.</p><p style="text-align: justify;">Last one week high and low of the scrip stood at Rs. 3822.70 and Rs. 3616.85 respectively. The current market cap of the company is Rs. 99602.48 crore.</p><p style="text-align: justify;">The promoters holding in the company stood at 51.92%, while Institutions and Non-Institutions held 36.74% and 11.34% respectively.</p><p style="text-align: justify;">Divi's Laboratories has reported results for third quarter ended December 31, 2023 (Q3FY24).</p><p style="text-align: justify;">The company has reported 15.48% rise in its net profit at Rs 358 crore for the third quarter ended December 31, 2023 as compared to Rs 310 crore for the same quarter in the previous year. Total income of the company increased by 5.26% at Rs 1902 crore for Q3FY24 as compared Rs 1807 crore for corresponding quarter of the previous year. </p><p style="text-align: justify;">On consolidated basis, the company has reported 16.99% rise in net profit at Rs 358 crore for Q3FY24 as compared to Rs 306 crore for the same quarter in the previous year. Total income of the company increased by 7.08% at Rs 1950 crore for Q3FY24 as compared Rs 1821 crore for corresponding quarter of the previous year. </p> |
| 09-Jan-2024 | Divi's Laboratories informs about certificate | <p style="text-align: justify;">Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, Divi's Laboratories has submitted a certificate for the quarter ended December 31, 2023 received from KFin Technologies, Registrar & Share Transfer Agent of the Company.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 30-Dec-2023 | Divi's Laboratories informs about closure of trading window | <div style="text-align: justify;">Pursuant to the Company's Code of Conduct for Prevention of Insider Trading (the Code), Divi's Laboratories has informed that the trading window for dealing in securities of the Company will remain closed for all Designated Persons and their Immediate Relatives, as well as Insiders covered under the Code, from January 01, 2024, till 48 hours after the declaration of unaudited financial results for the quarter and nine months ending December 31, 2023. The date of Board meeting for declaration of the unaudited financial results of the Company for the quarter and nine months ending December 31, 2023, will be intimated in due course.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div> |
